Stable cannabinoid formulations

Abstract

The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.

1 - 25 . (canceled) 
     
     
         26 . A method for treating infantile spasms in a subject, comprising administering to the subject a composition comprising cannabidiol, wherein the cannabidiol has a purity of greater than 98% w/w and wherein the dose of cannabidiol is about 20 to about 100 mg of cannabidiol per kg weight of the subject per day. 
     
     
         27 . (canceled) 
     
     
         28 . The method of  claim 26 , wherein the infantile spasms are refractory infantile spasms. 
     
     
         29 . The method of  claim 26 , wherein the dose of cannabidiol is about 20 to about 30 mg of cannabidiol per kg weight of the subject per day. 
     
     
         30 . The method of  claim 26 , wherein the dose of cannabidiol is about 20 mg of cannabidiol per kg weight of the subject per day. 
     
     
         31 . The method of  claim 26 , wherein the dose of cannabidiol is about 30 mg of cannabidiol per kg weight of the subject per day. 
     
     
         32 . The method of  claim 26 , wherein the dose of cannabidiol is about 100 mg of cannabidiol per kg weight of the subject per day. 
     
     
         33 . The method of  claim 26 , wherein the composition is a liquid solution. 
     
     
         34 . The method of  claim 26 , wherein the composition does not contain alcohol. 
     
     
         35 . The method of  claim 26 , wherein the cannabidiol is a synthetically prepared cannabidiol. 
     
     
         36 . The method of  claim 26 , wherein the composition comprises about 10 to about 32% w/w of cannabidiol. 
     
     
         37 . The method of  claim 26 , wherein the composition comprises:
 about 10 to about 32% w/w of cannabidiol;   about 60 to about 95% of a lipid; and   an antioxidant.   
     
     
         38 . The method of  claim 37 , wherein the lipid comprises caprylic/capric triglycerides. 
     
     
         39 . The method of  claim 37 , wherein the composition comprises about 0.01 to about 1% w/w of an antioxidant. 
     
     
         40 . The method of  claim 37 , wherein the antioxidant is alpha-tocopherol. 
     
     
         41 . The method of  claim 26 , wherein the subject is a human subject with West syndrome.